Dr. Hamid on Epacadostat Plus Pembrolizumab in Advanced Melanoma

Video

Omid Hamid, MD, director of the melanoma center at the Angeles Clinic & Research Institute in Los Angeles, discusses the phase III results of the ECHO-202/KEYNOTE-037 trial, which explored the IDO inhibitor epacadostat plus pembrolizumab (Keytruda) in patients with advanced melanoma.

Omid Hamid, MD, director of the melanoma center at the Angeles Clinic & Research Institute in Los Angeles, discusses the phase I/II results of the ECHO-202/KEYNOTE-037 trial, which explored the IDO inhibitor epacadostat plus pembrolizumab (Keytruda) in patients with advanced melanoma.

This was consistent with the initial results of the phase I trial, which demonstrated an overall response rate at around 55%, a disease control rate of about 70%, and an 18-month progression-free survival rate at more than 50%. Additionally, this was a very tolerable regimen that was not associated with significant toxicities.

This is important because prior combination therapies have shown similarly high response rates, but are linked with significant grade 3/4 toxicities—usually at 50%. Whereas, this combination showed grade 3/4 events at around 20% and a less than 10% grade 3/4 immune-related toxicities. This is a regimen that, if it shows benefit, then it is very translatable into the community, Hamid says. The phase III trial is currently ongoing, he concludes.

<<< View more from the 2017 ESMO Congress

Related Videos
Patrick I. Borgen, MD
Kari Hacker, MD, PhD, NYU Grossman School of Medicine
Janos L. Tanyi, MD, PhD, associate professor, Obstetrics and Gynecology, Hospital of the University of Pennsylvania
Reshma Lillaney Mahtani, DO
Christian Marth, MD, PhD, head, professor, Department of Obstetrics and Gynecology, Innsbruck Medical University
Mansoor Raza Mirza, MD, chief oncologist, Department of Oncology, Rigshospitalet, Copenhagen University Hospital
Judy Hayek, MD, gynecologic oncology fellow, State University of New York (SUNY) Downstate College of Medicine
Leslie M. Randall, MD, MAS, professor, division head, Department of Obstetrics and Gynecology – Gynecologic Oncology, Virginia Commonwealth University School of Medicine Obstetrics and Gynecology
Dimitrios Nasioudis, MD, fellow, Gynecologic Oncology, Perelman School of Medicine, the University of Pennsylvania
Sara Corvigno, MD, PhD, translational researcher, oncology, The University of Texas MD Anderson Cancer Center